---
title: "Escherichia coli"
---
# Escherichia coli
`disease · bacterium · gram-negative · synthetic-biology · metabolic-engineering · antimicrobial-target · biotechnology-chassis`

Last modified 2026-06-04 · 8 papers · 1 outgoing link · 4 incoming links

| | |
|---|---|
| **Type** | Gram-negative bacterium |
| **Role** | Pathogen and biotechnology chassis |
| **Key technologies** | CRISPR, metabolic engineering, ALE |
| **Compounds produced** | Salidroside (35.3 g/L), 1,4-BDO (7.5 g/L) |
| **Detection** | CRISPR/Cas12a, copper nanoclusters |
| **Antimicrobials** | Ianthelliformisamines, chitosan hydrogels |
| **Cancer therapy** | Biohybrid STING activation |
| **Papers** | 8 indexed |

---

**Escherichia coli** (E. coli) is a gram-negative bacterium that functions as both a pathogenic organism susceptible to novel antimicrobial compounds and the premier microbial chassis for synthetic biology and metabolic engineering applications. As a clinical pathogen, E. coli serves as a target for programmable CRISPR/Cas12a detection systems employing [[copper-nanoclusters]], achieving picomolar sensitivity in diagnostic assays,¹ and exhibits high susceptibility to natural products such as [[ianthelliformisamines]], which dually target ribosomal protein biosynthesis initiation (InfA) and flagellum assembly (FliC).² As a biotechnology platform, E. coli has been extensively engineered using CRISPR interference systems and adaptive laboratory evolution to produce pharmaceutical intermediates including salidroside (35.3 g/L titer) and platform chemicals such as [[1-4-butanediol]] (7.5 g/L titer) in antibiotic-free bioreactor fermentations.³⁴ Most recently, genetically engineered E. coli strains have been repurposed as programmable biohybrid delivery vehicles for cancer immunotherapy, exploiting hypoxic tropism for tumor-targeted release of STING pathway activators and copper-based cuproptosis inducers.⁵

---

## Synthetic biology platform

E. coli serves as the foundational chassis for synthetic biology due to its well-characterized genetics, rapid growth, and amenability to genetic manipulation. Adaptive laboratory evolution (ALE) has emerged as a powerful strategy for enhancing strain performance beyond rational engineering, with evolved strains exhibiting markedly enhanced tolerance to toxic precursors after 176 generations of selective pressure.³ Whole-genome sequencing and transcriptional analysis of ALE-derived strains reveals spatiotemporal synergy between upregulated glutamate transporters that mitigate oxidative stress (GltS) and mutations in regulatory proteins (RobA) that modulate efflux pump activity to control intracellular precursor availability.³ This precursor retention mechanism maintains high intracellular substrate concentrations necessary for efficient downstream catalysis without compromising cell viability, resolving the tolerance-yield trade-off inherent in engineering microbial cell factories for toxic intermediates.

---

## Metabolic engineering applications

E. coli strains engineered through coordinated regulation of pathway enzymes and enhancement of rate-limiting steps have achieved production of salidroside, a valuable phenolic glycoside from Rhodiola rosea with significant pharmaceutical potential, at titers of 6.3 g/L in shake flasks and 35.3 g/L in fed-batch bioreactor fermentations with tyrosol feeding.³ The evolved strain SA40, generated through ALE and expressing the UDP-glycosyltransferase AtUGT85A1, overcomes the toxicity of the precursor tyrosol through synergistic mutations in the glutamate transporter GltS and the transcriptional regulator RobA, which finely modulates the AcrAB efflux pump to balance intracellular substrate availability for glycosylation.³

Production of [[1-4-butanediol]] (1,4-BDO), a non-natural platform chemical for biodegradable plastics, has been constrained by inadequate NADPH availability required for the reductive steps in its biosynthetic pathway.⁴ Introduction of five heterologous enzymes, combined with precursor engineering to increase succinyl-CoA availability and strengthening of endogenous NADPH-generating pathways through an intracellular biohybrid system, increased intracellular NADPH levels by 73% and achieved 1,4-BDO titers of 7.5 g/L in plasmid-free, antibiotic-free, and inducer-free bioreactor fermentations.⁴ This scale-up feasible strategy demonstrates the potential for biosynthesis of NADPH-dependent diols in industrial settings.

---

## CRISPR systems and strain engineering

CRISPR/Cas12a systems integrated with DNA-templated [[copper-nanoclusters]] enable programmable bacterial DNA detection with picomolar sensitivity and high specificity through a one-pot fluorescence assay.¹ The assay exploits the collateral cleavage activity of activated Cas12a/gRNA complexes to degrade rationally designed DNA templates that support copper nanocluster formation, resulting in marked fluorescence decrease upon target recognition.¹ An AT-rich stem-loop reporter optimized for maximum fluorescence intensity and complete signal shutdown accurately detects E. coli DNA from reference strains, clinical isolates, and serum-spiked samples without requiring fluorophore-quencher probes or multistep procedures, offering a sustainable alternative to conventional fluorophores for point-of-care diagnostics.¹

CRISPR interference (CRISPRi) systems employing catalytically dead Cas9 (dCas9) or Cas12a (dCas12a) variants enable programmable sequence-specific transcriptional silencing in E. coli, though strain-specific effects on repression efficiency and host toxicity present important limitations when translating systems from laboratory to clinical contexts.⁶ Systematic evaluation across laboratory strain K-12 MG1655 and clinical isolates Nissle 1917 (probiotic), CFT073 (uropathogenic), and UMN026 (uropathogenic) reveals notable variation in growth toxicity from dCas protein expression and poorer repression in multiple clinical strains compared to the laboratory reference.⁶ A dual guide RNA CRISPRi system developed to enhance gene silencing across diverse genetic backgrounds achieves up to 824-fold repression in the uropathogenic strain CFT073, demonstrating that strain-specific design considerations arise when transferring genetic systems from model to nonmodel organisms.⁶

---

## Antimicrobial susceptibility

Natural product-derived [[ianthelliformisamines]] inhibit E. coli through dual mechanisms targeting InfA, a factor involved in the initiation of bacterial ribosomal protein biosynthesis, and FliC, a structural component crucial for flagellum assembly and motility.² Activity-based chemical proteomics employing synthesized ianthelliformisamine analogs and a chemical probe for activity-based protein profiling reveals that all molecules retain antibacterial effects enhanced in the presence of bicarbonate, an abundant ingredient of human serum.² Translation assays confirm InfA as an essential target for bacterial growth inhibition, while motility assays and transmission electron microscopy demonstrate impaired motility and disrupted flagellum assembly consistent with FliC targeting.² This dual antibacterial and antivirulence profile reduces invasion of pathogenic E. coli into human host cells, illustrating how chemical proteomics can uncover previously unrecognized cellular targets for poorly characterized natural product scaffolds and support further therapeutic development.

Engineered [[conductive-multifunctional-hydrogel]] formulations incorporating dopamine-functionalized reduced graphene oxide, alginate, and thymol-loaded chitosan nanoparticles exhibit superior antibacterial activity against E. coli, with inhibition zones of approximately 23 mm and >99% bacterial inhibition efficacy.⁷ The hydrogel achieves conductivity comparable to human skin (3.95 mS·cm⁻¹), strong bioadhesion (∼8.26 kPa), excellent hemocompatibility (hemolysis rates <0.2%), and high biocompatibility (>90% cell viability in 3T3 fibroblasts), demonstrating great potential as an advanced wound dressing for skin tissue engineering and wound healing promotion.⁷ The mechanism of antibacterial action is linked to disruption of bacterial cell membrane integrity.

Similarly, cyclodextrin-based deep eutectic solvent-constructed chitosan eutectogels delivering [[glabridin]], a natural product with wound repair potential, demonstrate over 99% antibacterial efficacy against both Staphylococcus aureus and E. coli through disruption of bacterial cell membrane integrity.⁸ The eutectogel system integrates a deep eutectic solvent formed from sulfobutyl ether-β-cyclodextrin and levulinic acid with chitosan through supramolecular interactions, simultaneously addressing the poor solubility and low photostability of glabridin while enabling sustained release for over 10 days.⁸ In an infected diabetic wound model, the glabridin-loaded eutectogel significantly accelerated wound healing, achieving a wound closure rate of 94.3% by day 21 through amelioration of the immune microenvironment, promotion of angiogenesis, and scavenging of reactive oxygen species.⁸

---

## Cancer immunotherapy applications

Genetically engineered E. coli strains function as programmable biohybrid delivery vehicles for cancer immunotherapy, exploiting the natural hypoxic tropism of facultative anaerobes for selective tumor accumulation.⁵ The DacA-Bac system, programmed through synthetic biology approaches to produce cyclic di-adenosine monophosphate (CDA), a STING pathway activator, is functionalized with copper-sulfide nanoparticles (Cu-SF) to enable dual-mode therapy combining immunostimulation with copper-overload-mediated cuproptosis.⁵ Under laser irradiation, spatiotemporally controlled CDA release ensures precise STING agonist delivery to the tumor site, overcoming key limitations of passive nanocarrier delivery systems including off-target toxicity and immunogenicity.⁵

The biohybrid system responsively dissociates in the tumor microenvironment, releasing copper ions to induce copper-overload-mediated cuproptosis, a novel copper-mediated programmed cell death mechanism distinct from apoptosis and ferroptosis.⁵ CDA-induced STING activation amplifies cuproptosis by disrupting glycolysis in tumor cells, which normally protects against copper toxicity, thereby boosting overall synergistic therapeutic efficacy.⁵ This combination treatment enhances dendritic cell maturation, promotes CD8⁺ T cell infiltration and activation, and establishes durable antitumor immunity, demonstrating that engineered bacteria can serve as living therapeutics that combine metabolic disruption with immunostimulation in the tumor microenvironment for high-efficiency tumor-targeted precise immunotherapy.

---

## References

1. PMID:41679990 — Copper nanoclusters as programmable reporters for CRISPR/Cas12a bacterial DNA detection
2. PMID:42012457 — Ianthelliformisamines inhibit protein translation and block flagellum assembly
3. PMID:41979105 — Adaptive laboratory evolution for enhanced tyrosol tolerance and salidroside production
4. PMID:41981749 — Engineering precursor and NADPH supply for 1,4-butanediol production
5. PMID:41401569 — Programmable bacteria-driven biohybrid triggers STING activation for cuproptosis-based cancer therapy
6. PMID:42068556 — Cross-strain transferability of CRISPRi systems in Escherichia coli strains
7. PMID:41831951 — Electroactive dopamine-functionalized hydrogel with thymol/chitosan nanoparticles for wound dressings
8. PMID:42003408 — Cyclodextrin-based eutectogel for glabridin delivery in diabetic wound management